BioRestorative Therapies, Inc.

Good afternoon, everyone, and welcome to the Bio-Restorative Therapies 2024 Results Conference Call. At this time, all participants are in a listen-only mode, and if anyone should require operator assistance during this conference, please press star zero on your phone keypad. Please note, this conference is being recorded. I will now turn the conference over to your host, Stephen Kilmer, Investor Relations. Sir, the floor is yours.

Thank you, Jenny. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are based on biorestorative therapy's current beliefs, assumptions, and expectations, and such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. no forward-looking statement can be guaranteed. For details on factors, among others, that could affect expectations, see Part 1, Item 1A of our annual report on Form 10-K for the year ended December 31st, 2024, which will be filed with the Securities and Exchange Commission. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date of this conference call. BioRestorative undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law. On the call representing the company are Lance Allstatt, BioRestorative's chairman and chief executive officer, Francisco Silva, its vice president of research and development, and Rob Crystal, the company's chief financial officer. With that said, I'm now turning the call over to Lance.

Thank you, Steve, and good afternoon, everyone. Welcome. On behalf of the management team and everyone at BioRestorative, I'd like to thank you for your interest in our company. And for those of you who are shareholders, we, of course, appreciate your support. As you can see from the press release we issued a short time ago, we continue to execute well across all areas of our business in 2024. And we have a lot of exciting things to look forward to as we move through 2025. With that said, I'd like to ask Rob, our Chief Financial Officer, to provide a brief overview of our 2024 financial results.